I used google translate to translate this article, in the last paragraph it looks like Sungen raised 2 million bucks.
ENGLISH
Recently, the listed company Jingfeng Pharmaceutical released the 2017 semi-annual results report, the reporting period, the company achieved a total operating income of 907.7997 million yuan, down 7.69% over the same period last year; operating profit of 96.3657 million yuan, down from the same period last year 31.71%; to achieve the attributable to shareholders of listed companies net profit of 58.7023 million yuan, down 50.56% over the same period last year; operating activities generated net cash flow of 1856.12 million yuan, an increase of 172.92% over the same period last year. It is understood that the core products of Jing-feng medicine by the ginseng glucose injection, sodium hyaluronate injection, elemene injection and oral milk, heart brain capsule composition. Jingfeng medicine, the company's main products for the prescription drugs, all public hospitals to purchase drugs to participate in the provincial drug centralized bidding procurement, after winning directly through the channels through the pharmaceutical business enterprises sold to hospitals. "If the company's drugs in the existing sales area can not be successful or because the bid price to reduce the strategic rejection of the company's profitability may have a negative impact." Jingfeng Pharmaceutical published data show that from the product point of view, the company's injection products in the first half of this year's operating income of 630 million yuan, down 14.26% year on year. Solid preparations operating income of 120 million yuan, down 0.25% year on year. Jingfeng Pharmaceutical said that during the reporting period, the company continued to implement the long-term strategic layout, increased investment in product development and medical services, as well as by the country a number of regions, the market tender price reduction and other adverse factors, Overall performance has declined. In 2016, the core varieties of Jingfeng medicine is faced with the pressure of bidding price. Jingfeng Pharmaceutical introduced, the main products of Shengxiong glucose injection of most of the country to achieve steady growth, but by the local market did not bid, the overall sales revenue fell by 10% compared with 2015, sodium hyaluronate injection by the tender price changes, sales revenue More than 16% decline in 2015; elemene injection, elemene oral milk, heart brain capsule sales over the same period last year made a relatively large increase. Guolian Securities analysis report has pointed out that the injection industry tender price pressure is greater, King Fung medicine in Fujian and other provinces abandoned the standard lead to the main varieties of Xianxie glucose injection revenue fell slightly. Jingfeng Pharmaceutical in the semi-annual report of 2017, "under the control of the national tender policy and the impact of the second bargaining the hospital, the company's products are facing a number of regional market prices." Marketing center to adjust the marketing strategy to deal with the marketing system as a transition opportunity to carry out sales integration and mode conversion, and gradually the agent, outsourcing of hospitals into self-mode, to strengthen the terminal control to fully tap the value of the product. At the same time to strengthen the multi-center clinical trials and clinical research, strengthen product promotion, expand the price reduction of the product market self-employed team, cost savings, and gradually move towards efficient academic marketing. In addition, Jingfeng Pharmaceutical layout of the health services in the field of health services, including Jinsha Hospital, Yunnan Dayton Orthopedic Hospital, Yunnan Dayton Maternity Hospital. Jingfeng Pharmaceutical has also made a number of investments, including: Jingfeng Pharmaceutical invested 27 million yuan to obtain 20% stake in Yi Kang Yun. The company said that the cooperation is conducive to the company to build online medical collaboration cloud platform and online clinical education platform to create a different level of doctors between the doctor's medical system and online education system; company invested 60 million yuan to participate in investment Jinyan investment Two), with the partner's financial strength and management team's investment management capabilities, and actively seek investment in health and health care in the field of high-quality assets. Jinzi invested in a nutritional treatment project with an investment of RMB 30 million. The Company acquired 30% equity interest in Jingcheng Pharmaceuticals and raised US $ 2 million to Sungen Pharma, LLC through its controlling subsidiary Sheng Jingmei Asia.
AI
